Kasper Karlsson

Karolinska Institutet

Key Publications
Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [177Lu]Lu-DOTATATE: results from the LuDO-N trial
European Journal of Nuclear Medicine and Molecular Imaging, 2026
Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids
Nature Materials, 2024
Engineered extracellular matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids
2022
Deterministic evolution and stringent selection during pre-neoplasia
2022
A CRISPR/Cas9-Engineered <i>ARID1A</i>-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation.
Cancer discovery, 2021

I work with translational medicine using tumor evolutionary principles, with a current focus on pediatric cancers. I am particularly interested in finding ways to target tumor metastases, needed to achieve cure in most cases. For this we use three orthogonal approaches:

1. Develop new methods to efficiently combine drugs specifically designed to overcoming tumor heterogeneity.

2. Develop new drugs, including radiopharmaceuticals.

3. Develop new cell culture and animal models.

Last updated: 2025-03-11

Content Responsible: Hampus Pehrsson Ternström(hampus.persson@scilifelab.uu.se)